Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros

Base de dados
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
J Cosmet Dermatol ; 23(5): 1583-1587, 2024 May.
Artigo em Inglês | MEDLINE | ID: mdl-38279518

RESUMO

OBJECTIVE: By presenting a case study on multiple instances of Bowen's disease and the consistent use of narrow-band ultraviolet B (NB-UVB) phototherapy over a three-year period, our aim is to enhance the comprehension of domestic clinicians regarding the disease. Additionally, we seek to review existing literature, encouraging dermatologists to consider clinical secondary primary lesion diagnoses. METHOD: Our approach involves analyzing a diagnosed case of multiple Bowen's disease, examining clinical manifestations, histopathology, imaging results, and treatment methods related to NB-UVB phototherapy. We aim to facilitate discussion and understanding through a comprehensive literature analysis. RESULTS: An elderly male with a 30-year history of psoriasis vulgaris initiated continuous NB-UVB therapy three years ago. A year later, he developed red patches and plaques with distinct borders and scaly surfaces on his face, trunk, lower extremities, and scrotum. Histopathological examination confirmed Bowen's disease. Treatment involved liquid nitrogen cryotherapy, with no recurrence observed during the one-year follow-up. CONCLUSION: This case highlights that Bowen's disease, typically solitary, can manifest as multiple instances, especially in individuals with a history of psoriasis vulgaris. While NB-UVB stands as the primary treatment for psoriasis vulgaris, caution is warranted due to the potential risk of skin tumor induction with prolonged high-dose usage. Clinicians should be vigilant in monitoring and assessing the long-term implications of such therapies.


Assuntos
Doença de Bowen , Psoríase , Neoplasias Cutâneas , Terapia Ultravioleta , Humanos , Doença de Bowen/terapia , Doença de Bowen/diagnóstico , Doença de Bowen/patologia , Masculino , Terapia Ultravioleta/efeitos adversos , Terapia Ultravioleta/métodos , Neoplasias Cutâneas/etiologia , Neoplasias Cutâneas/patologia , Neoplasias Cutâneas/radioterapia , Neoplasias Cutâneas/diagnóstico , Psoríase/diagnóstico , Psoríase/radioterapia , Psoríase/terapia , Idoso , Crioterapia/efeitos adversos
2.
Sci Rep ; 5: 9656, 2015 Apr 13.
Artigo em Inglês | MEDLINE | ID: mdl-25866290

RESUMO

Drug-based treatments are the most widely used interventions for cancer management. Personalized drug response profiling remains inherently challenging with low cell count harvested from tumour sample. We present a 96well-formatted microfluidic plate with built-in micro-gap that preserves up to 99.2% of cells during multiple assay/wash operation and only 9,000 cells needed for a single reagent test (i.e. 1,000 cells per test spot x 3 selected concentration x triplication), enabling drug screening and compatibility with conventional automated workstations. Results with MCF7 and MDA-MB-231 cell lines showed that no statistical significance was found in dose-response between the device and conventional 96-well plate control. Primary tumour samples from breast cancer patients tested in the device also showed good IC50 prediction. With drug screening of primary cancer cells must consider a wide range of scenarios, e.g. suspended/attached cell types and rare/abundant cell availability, the device enables high throughput screening even for suspended cells with low cell count since the signature microfluidic cell-trapping feature ensures cell preservation in a multiple solution exchange protocol.


Assuntos
Antineoplásicos/farmacologia , Avaliação Pré-Clínica de Medicamentos/métodos , Resistencia a Medicamentos Antineoplásicos , Idoso , Antineoplásicos/uso terapêutico , Neoplasias da Mama/diagnóstico , Neoplasias da Mama/tratamento farmacológico , Neoplasias da Mama/patologia , Linhagem Celular Tumoral , Relação Dose-Resposta a Droga , Feminino , Humanos , Técnicas In Vitro , Pessoa de Meia-Idade , Neoplasias/diagnóstico , Neoplasias/tratamento farmacológico
3.
J Cosmet Laser Ther ; 15(3): 126-32, 2013 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-23383957

RESUMO

BACKGROUND AND OBJECTIVE: A variety of laser and IPL treatments with continued progress have been applied for nonablative skin rejuvenation; however, the complete understanding of working mechanisms and clinical appliance strategy is not clear. MATERIALS AND METHODS: The rats were divided into three groups and irradiated with Q-switched 1064 nm Nd:YAG laser and IPL. Image analysis, chemical colorimetry method, and real-time PCR (RT-PCR) were used to detect the dermal thickness, hydroxyproline, and the expression of III procollagen mRNA, respectively, at sequential time points following irradiation. In addition, the ultra-structure changes of rat skin were observed by TEM at 3 weeks after irradiation. RESULTS: Two-light treatment contributed to increase in the dermal thickness, the hydroxyproline contents and the expression of III procollagen mRNA, and the dense arrangement of collagen. The effect of collagen synthesis and remodeling could last for at least 3 months after treatment, and the YAG group is more efficient than the IPL group. The expressions of procollagen type III mRNA reached peak level at 2 weeks. CONCLUSION: The effect of different lights depends on the wavelength and the penetrated depth; the best referential treatment interval of two kinds of lights for nonablative skin rejuvenation on rat skin is 2 weeks.


Assuntos
Terapia de Luz Pulsada Intensa , Lasers de Estado Sólido/uso terapêutico , Pele/efeitos da radiação , Análise de Variância , Animais , Feminino , Hidroxiprolina/metabolismo , Pró-Colágeno/metabolismo , RNA Mensageiro/metabolismo , Ratos , Ratos Wistar , Reação em Cadeia da Polimerase em Tempo Real , Rejuvenescimento , Pele/metabolismo , Pele/ultraestrutura
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA